8-K: Sensus Healthcare Appoints Eric Sachetta to Board

Sensus Healthcare, Inc. announced the appointment of Eric Sachetta as a Class II director, filling a vacancy and joining the Audit Committee.

Summary

• Sensus Healthcare, Inc. appointed Eric Sachetta as a Class II director to its Board of Directors, effective November 10, 2025.
• Mr. Sachetta fills the vacancy created by the passing of long-serving Director William McCall.
• He will serve a term expiring at the company's annual meeting in 2026.
• The Board has determined Mr. Sachetta to be an independent director within the meaning of Rule 5605(a)(2) of The NASDAQ Stock Market, LLC listing standards.
• Mr. Sachetta has been appointed as a member of the Audit Committee of the Board.
• Mr. Sachetta, age 37, is the Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm, where he leads the financial advisory division and oversees wealth management operations.
• He holds a Bachelor of Science in Corporate Finance & Accounting from Bentley University and is a Certified Financial Planner (CFP), Chartered Financial Consultant (ChFC), Tax Planning Certified Professional (TPCP), and holds a Series 65 investment advisory license.

Sentiment

Score: 7

Explanation: The appointment of a qualified, independent director to fill a vacancy is a positive governance step, bringing new expertise to the board and the Audit Committee. The underlying reason for the vacancy (death of a director) is negative, but the company has addressed it promptly with a strong candidate.

Positives

• Appointment of Eric Sachetta, a seasoned financial executive, to the Board of Directors.
• Mr. Sachetta brings leadership acumen, strategic growth expertise, and a strong track record of operational excellence.
• His background includes extensive experience in financial advisory, organizational growth, team development, and operational improvement.
• His qualifications as a Certified Financial Planner and other financial certifications enhance the board's financial expertise.
• Appointment to the Audit Committee strengthens the company's financial oversight and governance.
• The Board determined Mr. Sachetta is an independent director, reinforcing corporate governance standards.

Negatives

• The appointment fills a vacancy on the Board resulting from the death of long-serving Director William McCall.

Risks

• The possibility that inflationary pressures continue to impact sales.
• The level and availability of government and/or third-party payor reimbursement for clinical procedures using products, and the willingness of healthcare providers to purchase products if reimbursement declines.
• Concentration of customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.
• The development by others of new products, treatments, or technologies that render Sensus' technology partially or wholly obsolete.
• The regulatory requirements applicable to Sensus and its competitors.
• Ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries.
• Legislation, regulation, or other governmental action that affects products, taxes, international trade regulation, or other aspects of the business.
• The performance of the company's information technology systems and its ability to maintain data security.
• Ability to obtain and maintain the intellectual property needed to adequately protect products, and ability to avoid infringing or otherwise violating the intellectual property rights of third parties.

Future Outlook

The filing contains general forward-looking statements regarding potential risks to the company's operations, financial condition, and liquidity, including inflationary pressures, reimbursement levels, customer concentration, technological obsolescence, regulatory changes, manufacturing costs, international business risks, IT system performance, and intellectual property protection. No specific financial guidance or projections were provided.

Management Comments

• "I have been closely following Sensus Healthcare for many years and am impressed with the company’s commitment to patient care and superior clinical outcomes through the delivery of non-invasive treatments for non-melanoma skin cancer and keloids." Eric Sachetta
• "Sensus has an outstanding leadership team and I look forward to contributing to the long-term success of the company." Eric Sachetta
• "We are delighted to welcome Eric to our Board and look forward to his contributions." Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare
• "Eric brings a strong financial background, deep experience leading organizations through growth and transition and a clear appreciation for the mission of our company." Joe Sardano
• "We believe that his combination of strategic insight and people-focused leadership will add meaningful value as we continue expanding the reach of our SRT technology and advancing our global vision." Joe Sardano

Industry Context

Sensus Healthcare operates in the medical device industry, specializing in superficial radiotherapy (SRT and IG-SRT) technology for non-invasive treatments of skin cancer and keloids. The appointment of a director with strong financial and strategic growth expertise is a common practice for companies in this sector looking to strengthen corporate governance and support expansion initiatives, especially given the complexities of healthcare reimbursement and regulatory environments.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from enhanced corporate governance, financial expertise, and strategic oversight on the Board and Audit Committee.
• Employees: May benefit from strengthened leadership and strategic direction provided by the Board.

Key Dates

Keywords

Sensus Healthcare, SRTS, Board of Directors, Director Appointment, Eric Sachetta, Corporate Governance, Audit Committee, Medical Device, Financial Advisory, Certified Financial Planner